Gracell Bio Shares Tumble as Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Receipt of ‘orphan drug’ designation for company’s CAR-T cancer drug in the U.S. will bring financial incentives, but also underscores drug’s limited market potential Key takeaways Gracell Bio stands to…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
Why JL Mag came unstuck, but is getting back on track
6680.HK 300748.SHE
-
As solar construction in China cools, Hainan Drinda looks for relief overseas
002865.SHE
-
Akeso marks profit milestone with swift rights issue
9926.HK
